These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 12602066)

  • 21. Watch for these new generics.
    Consum Rep; 2012 May; 77(5):12. PubMed ID: 22641866
    [No Abstract]   [Full Text] [Related]  

  • 22. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

  • 23. An ethical dilemma. Patents & profits v. access & affordability.
    Blasi AE
    J Leg Med; 2012 Jan; 33(1):115-28. PubMed ID: 22439710
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug patent protection: how long is long enough?
    Sibbald B
    CMAJ; 2001 May; 164(9):1331. PubMed ID: 11341146
    [No Abstract]   [Full Text] [Related]  

  • 25. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 26. AIDS drugs. Brazil, Thailand override big pharma patents.
    Cohen J
    Science; 2007 May; 316(5826):816. PubMed ID: 17495145
    [No Abstract]   [Full Text] [Related]  

  • 27. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 28. Drugmakers fight for good name. Stakes high, challenges many for providers who seek generic products.
    Becker C
    Mod Healthc; 2001 Aug; 31(35):28-33, 1. PubMed ID: 11550428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Federal regulation of medical devices.
    Kessler DA; Pape SM; Sundwall DN
    N Engl J Med; 1987 Aug; 317(6):357-66. PubMed ID: 3299097
    [No Abstract]   [Full Text] [Related]  

  • 30. Betting on biogenerics.
    Dove A
    Nat Biotechnol; 2001 Feb; 19(2):117-20. PubMed ID: 11175723
    [No Abstract]   [Full Text] [Related]  

  • 31. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 32. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 33. AWP reimbursement scrutinized by several states.
    Carroll J
    Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
    [No Abstract]   [Full Text] [Related]  

  • 34. Lowering Part D drug costs without direct CMS negotiations.
    Sipkoff M
    Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
    [No Abstract]   [Full Text] [Related]  

  • 35. Authorized generics.
    Glass G
    Nat Rev Drug Discov; 2005 Dec; 4(12):953-4. PubMed ID: 16370080
    [No Abstract]   [Full Text] [Related]  

  • 36. A brief history of generic substitution in the USA.
    Sullivan CG
    Pharm Pat Anal; 2012 Mar; 1(1):9-11. PubMed ID: 24236706
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-37. PubMed ID: 27116796
    [No Abstract]   [Full Text] [Related]  

  • 38. Protect pharmaceutical innovation.
    Musselwhite LW; Andrews J
    Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
    [No Abstract]   [Full Text] [Related]  

  • 39. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug; 18(16):6. PubMed ID: 14626916
    [No Abstract]   [Full Text] [Related]  

  • 40. CMS LAUNCHES 'OPEN PAYMENTS' SITE DESPITE PHYSICIAN CONCERNS.
    Ritchie A
    Med Econ; 2014 Oct; 91(20):50. PubMed ID: 26242084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.